{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:08:16Z","timestamp":1767985696815,"version":"3.49.0"},"reference-count":39,"publisher":"Georg Thieme Verlag KG","issue":"02","funder":[{"name":"Government funding of clinical research within the national health service, Lund University, Sweden"},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013297","name":"Eurostars","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013297","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003461","name":"Gunnar Nilssons Cancerstiftelse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003461","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuklearmedizin"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite new therapies, castration-resistant prostate cancer (CRPC) is still incurable. Intercellular Adhesion Molecule 1 (ICAM-1) is a well-characterized cell surface protein involved in prostate cancer pathogenesis, differentially expressed during transition from hormone-sensitive to CRPC. This study aimed to investigate ICAM-1 as a target for imaging and radioimmunotherapy of CRPC.<\/jats:p><jats:p>Anti-ICAM-1 antibody R6.5 was labeled with 111In or 177Lu, and a non-specific antibody with 177Lu. In vitro uptake of R6.5 was tested in PC-3 prostate cancer cells. Biodistribution studies, SPECT\/CT imaging, and autoradiography were performed in a PC-3 xenograft model.<\/jats:p><jats:p>In vitro uptake of R6.5 ([177Lu]Lu-R6.5) increased during 6 h of incubation. The uptake was higher at lower mAb concentration and could be blocked by 500 nM of unlabeled R6.5. In vivo and ex vivo biodistribution showed that [111In]In-R6.5 and [177Lu]Lu-R6.5 targeted the xenograft tumors better than the control Ab, however [111In]In-R6.5 had better tumor uptake than [177Lu]Lu-R6.5, probably due to less aggressive conjugation with chelator and smaller tumor sizes. From 24 h post-injection, the tumors in mice injected with [111In]In-R6.5 and [177Lu]Lu-R6.5 were visible on SPECT, optimal contrast at 48 h. Uptake was low in normal organs except the spleen and liver for all mAbs. Autoradiography showed [111In]In-R6.5 and [177Lu]Lu-R6.5 accumulated along the edges of viable tumor. The control Ab tended to accumulate in partly necrotic areas.<\/jats:p><jats:p>This study demonstrates ICAM-1 as a potential target for theragnostics in CRPC.<\/jats:p>","DOI":"10.1055\/a-2543-0723","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:25:46Z","timestamp":1742343946000},"page":"163-169","source":"Crossref","is-referenced-by-count":1,"title":["Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse model"],"prefix":"10.1055","volume":"64","author":[{"given":"Anders","family":"\u00d6rbom","sequence":"additional","affiliation":[{"name":"Section of Oncology, Lund University Department of Clinical Sciences Lund, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Evans-Axelsson","sequence":"additional","affiliation":[{"name":"Section of Urological cancers, Department of Translational Medicine, Lund University Faculty of Medicine, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Jansson","sequence":"additional","affiliation":[{"name":"Section of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lund University Faculty of Medicine, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oskar","family":"Vilhelmsson Timmermand","sequence":"additional","affiliation":[{"name":"Section of Oncology, Lund University Department of Clinical Sciences Lund, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thuy A.","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Radiopharmacy, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Bjartell","sequence":"additional","affiliation":[{"name":"Section of Urological cancers, Department of Translational Medicine, Lund University Faculty of Medicine, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven-Erik","family":"Strand","sequence":"additional","affiliation":[{"name":"Medical Radiation Physics, Lund University Department of Clinical Sciences Lund, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"7569","DOI":"10.1158\/1078-0432.CCR-17-2008","article-title":"CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors","volume":"23","author":"IM Min","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030635","article-title":"Treatment of Advanced Prostate Cancer \u2013 A Review of Current Therapies and Future Promise","volume":"8","author":"S Sumanasuriya","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/pros.20158","article-title":"Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines","volume":"63","author":"H Zhao","year":"2005","journal-title":"Prostate"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00109-009-0446-3","article-title":"Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion","volume":"87","author":"F Conrad","year":"2009","journal-title":"J Mol Med (Berl)"},{"key":"ref5","first-page":"553","article-title":"Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues","volume":"2","author":"SH Hayes","year":"2009","journal-title":"International journal of clinical and experimental pathology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/cancers9110153","article-title":"Role of LFA-1 and ICAM-1 in Cancer","volume":"9","author":"M Reina","year":"2017","journal-title":"Cancers"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/carcin\/bgs108","article-title":"CCN3 increases cell motility and ICAM-1 expression in prostate cancer cells","volume":"33","author":"PC Chen","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.7150\/thno.16752","article-title":"CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer","volume":"7","author":"C Li","year":"2017","journal-title":"Theranostics"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jcyt.2018.01.010","article-title":"Effect of irradiation-induced intercellular adhesion molecule-1 expression on natural killer cell-mediated cytotoxicity toward human cancer cells","volume":"20","author":"JU Jeong","year":"2018","journal-title":"Cytotherapy"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0165-5728(99)00248-9","article-title":"ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging","volume":"104","author":"DA Sipkins","year":"2000","journal-title":"Journal of neuroimmunology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/bit.20625","article-title":"Targeted ultrasound contrast agents: In vitro assessment of endothelial dysfunction and multi-targeting to ICAM-1 and sialyl Lewisx","volume":"92","author":"GE Weller","year":"2005","journal-title":"Biotechnology and bioengineering"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nucmedbio.2020.02.014","article-title":"Immuno-imaging of ICAM-1 in tumours by SPECT","volume":"84","author":"M Mosley","year":"2020","journal-title":"Nuclear Medicine and Biology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s00259-021-05216-3","article-title":"ImmunoPET\/NIRF\/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma","volume":"48","author":"M Li","year":"2021","journal-title":"European journal of nuclear medicine and molecular imaging"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189187","article-title":"Intercellular adhesion molecule-1 (ICAM-1): From molecular functions to clinical applications in cancer investigation","volume":"1879","author":"WJ Qian","year":"2024","journal-title":"Bba-Rev Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.4049\/jimmunol.144.12.4604","article-title":"In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts","volume":"144","author":"AB Cosimi","year":"1990","journal-title":"J Immunol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1161\/hs3211.098535","article-title":"Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study","volume":"32","author":"K Furuya","year":"2001","journal-title":"Stroke"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1212\/WNL.57.8.1428","article-title":"Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial","volume":"57","author":"EAST Investigators","year":"2001","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/00007890-199903150-00015","article-title":"A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group","volume":"67","author":"K Salmela","year":"1999","journal-title":"Transplantation"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000007962","article-title":"Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): an open-label, dose escalation study in patients hospitalized for acute stroke","volume":"40","author":"D Schneider","year":"1998","journal-title":"Eur Neurol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.4049\/jimmunol.162.4.2353","article-title":"Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood","volume":"162","author":"J Vuorte","year":"1999","journal-title":"J Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1118\/1.4905049","article-title":"Characterization of a double-sided silicon strip detector autoradiography system","volume":"42","author":"A \u00d6rbom","year":"2015","journal-title":"Medical Physics"},{"key":"ref22","first-page":"34","article-title":"Two functionally different follicular dendritic cells in secondary lymphoid follicles of mouse spleen, as revealed by CR1\/2 and FcR gamma II-mediated immune-complex trapping","volume":"80","author":"K Yoshida","year":"1993","journal-title":"Immunology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.3390\/cancers13143469","article-title":"A conjugation strategy to modulate antigen binding and FcRn interaction leads to improved tumor targeting and radioimmunotherapy efficacy with an antibody targeting prostate-specific antigen","volume":"13","author":"O Vilhelmsson Timmermand","year":"2021","journal-title":"Cancers"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1021\/bc300678y","article-title":"Influence of Nuclides and Chelators on Imaging Using Affibody Molecules: Comparative Evaluation of Recombinant Affibody Molecules Site-Specifically Labeled with 68Ga and 111In via Maleimido Derivatives of DOTA and NODAGA","volume":"24","author":"M Altai","year":"2013","journal-title":"Bioconjugate Chemistry"},{"key":"ref25","first-page":"103","article-title":"Tumor Uptake as a Function of Tumor Mass \u2013 a Mathematic Model","volume":"29","author":"LE Williams","year":"1988","journal-title":"Journal of Nuclear Medicine"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1023\/a:1025785505977","article-title":"Drug delivery and transport to solid tumors","volume":"20","author":"SH Jang","year":"2003","journal-title":"Pharm Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2967\/jnumed.110.083998","article-title":"Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system","volume":"52","author":"C Heneweer","year":"2011","journal-title":"J Nucl Med"},{"key":"ref28","first-page":"1191","article-title":"A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier","volume":"31","author":"K Fujimori","year":"1990","journal-title":"J Nucl Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.2967\/jnumed.111.092098","article-title":"Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET","volume":"52","author":"A Ruggiero","year":"2011","journal-title":"J Nucl Med"},{"key":"ref30","first-page":"610","article-title":"Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor","volume":"44","author":"PM Smith-Jones","year":"2003","journal-title":"J Nucl Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"AI Minchinton","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"T Lammers","year":"2012","journal-title":"J Control Release"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fonc.2013.00193","article-title":"Strategies to increase drug penetration in solid tumors","volume":"3","author":"IK Choi","year":"2013","journal-title":"Front Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.2967\/jnumed.112.117028","article-title":"The Intratumoral Distribution of Radiolabeled 177Lu-BR96 Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model","volume":"54","author":"A \u00d6rbom","year":"2013","journal-title":"J Nucl Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.7150\/thno.31179","article-title":"Preclinical efficacy of hK2 targeted [Lu-177]hu11B6 for prostate cancer theranostics","volume":"9","author":"OV Timmermand","year":"2019","journal-title":"Theranostics"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"13048","DOI":"10.1016\/S0021-9258(18)99982-5","article-title":"Isotype choice for chimeric antibodies affects binding properties","volume":"269","author":"MM Morelock","year":"1994","journal-title":"J Biol Chem"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1097\/01.TA.0000030626.84680.11","article-title":"Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury","volume":"54","author":"WJ Mileski","year":"2003","journal-title":"J Trauma"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1208\/s12248-016-9940-z","article-title":"Multiscale modeling of antibody-drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy","volume":"18","author":"C Cilliers","year":"2016","journal-title":"The AAPS journal"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/jps.22801","article-title":"Dose dependence of intratumoral perivascular distribution of monoclonal antibodies","volume":"101","author":"JJ Rhoden","year":"2012","journal-title":"J Pharm Sci"}],"container-title":["Nuklearmedizin - NuclearMedicine"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2543-0723.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T22:46:53Z","timestamp":1744930013000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2543-0723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":39,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,4,17]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2543-0723","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0029-5566","2567-6407"],"issn-type":[{"value":"0029-5566","type":"print"},{"value":"2567-6407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}